ÖÐÅ·ÌåÓý(Öйú)¹Ù·½ÍøÕ¾-APPÏÂÔØ

0512-6789 5080
info@zvxcbio.com
ÁªÏµ·½Ê½
ËÕÖÝÖÐÅ·ÌåÓý(Öйú)¹Ù·½ÍøÕ¾ÉúÎïÒ½Ò©¿Æ¼¼ÓÐÏÞ¹«Ë¾
Q  Q£º3440695713
µç»°£º0512-6789 5080
ÓÊÏ䣺info@zvxcbio.com
µØÖ·£º½­ËÕÊ¡ËÕÖÝÊй¤ÒµÔ°Çøԣз168ºÅÂöɽÁú´óÏÃ2´±
ÔÚÏß×Éѯ
ÃâÒß¹²´Ì¼¤Óë¹²ÒÖÖÆ £¨ÃâÒß¼ì²éµã£©
·¢²¼Ê±¼ä£º2024-07-01

ÖúÁ¦ÄúµÄÃâÒßµ÷½ÚÑо¿

Tϸ°ûÊÜÌå(T cell receptor, TCR)ʶ±ð¿¹Ô­µÝ³Êϸ°û(antigen presenting cells, APCs)ÉϵĿ¹Ô­ëÄ-MHC I/II¸´ºÏÎïºóÆô¶¯Tϸ°û½éµ¼µÄÃâÒßÓ¦´ð¡£È»¶ø£¬¿¹Ô­ëÄ-MHC I/II¸´ºÏÎïÓëTCRµÄÏ໥×÷Óò»×ãÒԻ³õʼ T ϸ°û£¬Ö»ÓжîÍâµÄ¹²´Ì¼¤(costimulatory)ÐźŲÎÓëʱ·½ÄÜÍêÈ«¼¤»îTϸ°û£¬´ÙʹTϸ°ûÔöÖ³²¢Ç¨ÒƵ½Ñ×Ö¢²¿Î»£¬È»ºóÖ±½Ó»ò¼ä½Óͨ¹ýÆäËüЧӦϸ°û»òÒò×Ó(Èçϸ°ûÒò×ÓµÈ) ¹¥»÷ºÍÆÆ»µ±í´ïÏà¹Ø¿¹Ô­µÄϸ°û¡£ÓÐЧµÄÃâÒßÓ¦´ðÊÇ»úÌåµÖÓùÍâÀ´²¡Ô­ÌåºÍ¶Ô¿¹¶ñÐÔÖ×ÁöËù±ØÐëµÄ£¬È»¶øµ±ÃâÒßÓ¦´ðʧµ÷ʱ£¬¿ÉÄÜ»á²úÉúÂýÐÔÑ×Ö¢£¬½ø¶øµ¼ÖÂ×éÖ¯ËðÉ˺Í×ÔÉíÃâÒß¼²²¡µÄ·¢Éú¡£

ÃâÒß¼ì²éµã(Immune checkpoints)ÊÇÃâÒßϵͳÖÐÆðÒÖÖÆ×÷Óõĵ÷½Ú·Ö×Ó£¬Æä¶ÔÓÚά³Ö×ÔÉíÄÍÊÜ¡¢·ÀÖ¹×ÔÉíÃâÒß·´Ó¦¡¢ÒÔ¼°Í¨¹ý¿ØÖÆÃâÒßÓ¦´ðµÄʱ¼äºÍÇ¿¶È¶øʹ×éÖ¯ËðÉË×îС»¯µÈÖÁ¹ØÖØÒª¡£ÕâЩÃâÒß¼ì²éµã¾­³£¹ý±í´ïÓÚÖ×Áöϸ°û»òÖ×Áö΢»·¾³ÖеÄδ¶ñ»¯Ï¸°ûÉÏ£¬Æä×÷ÓÃÊÇʹÃâÒßϵͳ²»ÄܲúÉúÓÐЧµÄ¿¹Ö×ÁöÓ¦´ð¡£ÃâÒßÓ¦´ðÊÇÓɹ²´Ì¼¤(co-stimulatory)ºÍÒÖÖÆÐźÅÖ®¼äµÄƽºâ(ͼ1)À´µ÷½ÚµÄ£¬½«Õâ¸öƽºâµ¼ÏòËùÆÚÍûµÄ·½Ïò¿ÉÓÃÓÚÖÎÁƺͻº½â¶àÖÖ¼²²¡¡£


ͼ1£º Tϸ°û¹²´Ì¼¤ºÍÒÖÖÆÐźš£Tϸ°ûÉϵĹ²´Ì¼¤·Ö×ÓÓëÆäÔÚAPCsÉϵÄÅäÌå½áºÏºó´«µÝÕýÐÔÐźţ¬¶øÒÖÖÆ(¼ì²éµã)·Ö×Ó´«µÝ¸ºÐÔÐźÅ¡£


×è¶ÏÃâÒß¼ì²éµãµÄÒÖÖÆ×÷ÓÃÊǵ±½ñÁÙ´²Éϼ¤»î¿¹Ö×ÁöÃâÒßÓ¦´ðºÍ¿ØÖƶàÖÖÖ×ÁöµÄÃâÒßÌÓÒÝ×î¾ßÇ°¾°µÄÊֶΡ£Ê׸öÃâÒß¼ì²éµã×è¶ÏÒ©ÎïÀ´×Ô°ÙʱÃÀÊ©¹ó±¦¹«Ë¾Ñз¢Éú²úµÄipilimumab¿¹Ìå(ÉÌÆ·ÃûΪYervoy)£¬¸Ã¿¹Ìå×÷ÓÃÓÚ CTLA-4(Cytotoxic
T-lymphocyte-associated antigen 4);¾¶£¬ÒÑ»ñFDA(ÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö)Åú×¼ÉÏÊС£½üÁ½Ä꣬FDAÓÖÅú×¼ÁËÁ½¸ö°ÐÏòPD-1(programmed celldeath protein 1)µÄÒ©Î·Ö±ðΪĬ¿Ë¹«Ë¾µÄPembrolizumab (ÉÌÆ·ÃûΪKeytruda)ºÍ°ÙʱÃÀÊ©¹ó

±¦¹«Ë¾µÄNivolumab(ÉÌÆ·ÃûΪOpdivo)¡£

¶ÔÃâÒßµ÷½Ú;¾¶µÄÉîÈëÀí½â´ßÉú³ö¶à¸öÖ×ÁöÖÎÁƵÄDZÔڰе㣬ÕâЩ°Ðµã¼äµÄЭͬЧӦҲÔÚÑо¿Ö®ÖС£

ÒÖÖÆÃâÒß¼ì²éµãͨ·µÄÖÎÁÆ·½·¨ÒýÆðÇ¿Á¦µÄ¿¹Ö×ÁöÃâÒßÓ¦´ðºÍÖ×ÁöÏûÍË£¬Ïà·´£¬Èç¹ûÀûÓüì²éµã·Ö×ÓµÄÒÖÖÆ×÷Óã¬ÓпÉÄÜ»º½â×ÔÉíÃâÒß¼²²¡ÖеÄÑ×Ö¢·´Ó¦£¬FDAÅú×¼µÄÈËÔ´»¯Èںϵ°°×CD152-IgG(Abatacept, ÉÌÆ·Ãû Orencia£¬°ÙʱÃÀÊ©¹ó±¦¹«Ë¾Éú²ú)¼´ÎªÒ»¸öÀýÖ¤¡£Abataceptͨ¹ýÑ¡ÔñÐÔ×è¶ÏÓÉCD28ºÍÆäÊÜÌåCD80/CD86Ï໥×÷ÓÃÒýÆðµÄ¹²´Ì¼¤ÐźŶøÒÖÖÆTϸ°ûµÄ»î»¯£¬´Ó¶ø·¢»ÓÒÖÖÆTϸ°ûÔöÖ³ºÍBϸ°ûÃâÒßÓ¦´ðµÄ¹¦Ð§¡£

¿ÉÒÔÔ¤¼û£¬ÈçÄܳä·Ö¼ì²é½þÈóµÄÃâÒßϸ°û¼°Æä±í´ïÃâÒßÒÖÖÆ·Ö×ÓµÄÇé¿ö£¬½«ÓÐÖúÓÚ¼ì²éµãÒÖÖƼÁºÍÃâÒß¼¤¶¯¼ÁÁªºÏÖÎÁÆ·½°¸µÄÓÅ»¯¡£

PeproTechÌṩ¶àÖÖÓÃÓÚ¹²´Ì¼¤ºÍÃâÒß¼ì²éµãͨ·Ñо¿µÄ¸ßÆ·ÖÊÊÔ¼Á£¬ÒÔÖúÁ¦ÃâÒßµ÷½ÚÁìÓòÈ¡µÃ½øÒ»²½µÄÍ»ÆÆ¡£

B7-CD28³¬¼Ò×å

B7¼Ò×åÅäÌåºÍCD28¼Ò×åÊÜÌå¾ùÊôÓÚÃâÒßÇòµ°°×³¬¼Ò×å(IgSF)£¬Á½ÕßÖ®¼äµÄÏ໥×÷ÓÃÒýÆðÕýÏòµÄ´Ì¼¤ÐźŻò¸ºÏòµÄÒÖÖÆÐźţ¬ÕâЩÐźÅΪµ÷½ÚTϸ°ûÓ¦´ðËù±ØÐ롣ĿǰÒÑÖª£¬B7¼Ò×åÓÐB7-1 (CD80),B7-2 (CD86), PD-L1(Programmed cell Death protein Ligand 1, B7-H1, CD274), PD-L2(Programmed cell Death protein Ligand 2, B7-DC,CD273), ICOSL(Inducible T cells Co-StimulatorLigand, B7-H2, CD275), B7-H3(CD276), B7-H4,B7-H5, B7-H6ºÍB7-H7(HHLA2)µÈ¶à¸ö³ÉÔ±£¬¶ø

CD28¼Ò×åÓÐ5¸ö³ÉÔ±£¬¼´CD28, CTLA4, ICOS, PD1ºÍBTLA (B- and T-Lymphocyte Attenuator)¡£

CD28ºÍB7-1/B7-2

CD28ÊÇB7ÊÜÌå¼Ò×åÖÐΨһһ¸ö×é³ÉÐͱí´ïÓÚ³õʼTϸ°û²¢Ìṩ¹²´Ì¼¤ÐźŵijÉÔ±¡£CD28ÓëÆäÅäÌåB7-1(CD80)ºÍB7-2(CD86)Ï໥×÷Óã¬ÒÔ¼°TCR(T-cellreceptor,Tϸ°ûÊÜÌå)½éµ¼µÄ´Ì¼¤Ðźţ¬¹²Í¬²ÎÓëTϸ°ûµÄ»î»¯¡¢ÔöÖ³¡¢Ï¸°ûÒò×Ó²úÉú¡¢ÒÔ¼°Tϸ°ûµÄ´æ»î¡£B7-1ÔÚAPCsÊܵ½TollÑùÊÜÌå(TLRs)´Ì¼¤Ê±Éϵ÷±í´ï£¬¶øB7-2×é³ÉÐͱí´ïÓÚAPCsÉÏ¡£

ICOSºÍICOSL

ICOS±í´ïÔڻµÄTϸ°ûÉÏ£¬¶øÆäÅäÌåICOSLÔÚBϸ°û¡¢¾ÞÊÉϸ°û¡¢µ¥ºËϸ°ûºÍÊ÷ͻ״ϸ°û(dendritic cells£¬DCs) µÈAPCsÉϱí´ï¡£ICOSÓëÆäÅäÌåICOSLµÄÏ໥×÷Óý鵼Tϸ°û»î»¯ºÍÔöÖ³£¬²¢²ÎÓëTϸ°ûÒÀÀµÐÔBϸ°û»î»¯ºÍ¸¨ÖúÐÔT(Th)ϸ°ûµÄ

·Ö»¯¡£

CTLA4ºÍB7-1/B7-2

CTLA4µÄ±í´ïµ±Tϸ°û»î»¯ºÍCD28½»ÁªÊ±Ñ¸ËÙÉϵ÷¡£CTLA4Ò²±í´ïÔÚµ÷½ÚÐÔTϸ°û(regulatory Tcells, Tregs)£¬ÒÔ¼°Ä³Ð©Õý³£ºÍ¶ñÐԵķÇTϸ°û±íÃæ¡£CTLA4ÓëCD28µÄÅäÌåÏàͬ£¬¾ùΪB7-1ºÍB7-2£¬µ«CTLA4µÄÇ׺ÏÁ¦±ÈCD28¸ß20-100±¶¡£

CTLA4Óë±í´ïÔÚAPCsÉϵÄB7-1ºÍB7-2ÅäÌåÏ໥×÷Ó㬿ÉÒÖÖÆϸ°ûÔöÖ³¡¢Ï¸°ûÒò×ӵIJúÉúºÍϸ°ûÖÜÆڵĽøÕ¹¡£CTLA4ÓëCD28¾ºÕùÐÔ½áºÏB7-1ºÍB7-2£¬´Ó¶ø×è¶ÏCD28·Ö×ӵĹ²´Ì¼¤Ðźţ¬Ê¹Tϸ°ûµÄ»î»¯¼°¹¦ÄÜ·¢»ÓÊÜÒÖ¡£»ùÓÚ×è¶ÏCTLAÒÖÖÆ×÷ÓõÄÃâÒßÖÎÁÆÒ©ÎïÒÑ»ñFDAÅú×¼¡£

PD1ºÍPD-L1/PD-L2

PD1Ö÷Òª±í´ïÔڻµÄ Tϸ°û£¬×ÔȻɱÉË(natural killer, NK)ϸ°û£¬Bϸ°ûºÍijЩËèϵϸ°ûÉÏ¡£ËüÒ²ÔÚ¶àÖÖ·ÇÔìѪϸ°ûÉϵͱí´ï£¬¶àÖִ̼¤Îï¾ù¿ÉʹÆäÉϵ÷±í´ï¡£ÒÑÖª£¬PD1ÓÐÁ½¸öÅäÌ壬·Ö±ðÊÇPD-L1ºÍPD-L2¡£PD-L1×é³ÉÐͱí´ïÓÚÃâÒßϸ°û

(ÈçTϸ°û£¬Bϸ°ûºÍDCs)ÒÔ¼°Ðí¶àÖ×Áö£¬PD-L2ÔòÓÉLPSºÍIFN-gÓÕµ¼±í´ïÓÚDCsºÍ¾ÞÊÉϸ°ûÉÏ¡£PD1ͨ¹ý·ÀÖ¹Tϸ°û»î»¯ºÍϵ÷ÃâÒßÓ¦´ð£¬ÔÚ½µµÍ×ÔÉíÃâÒß·´Ó¦ºÍ´Ù½ø×ÔÉíÄÍÊÜÖаçÑÝÖØÒª½ÇÉ«¡£PD1ÓÕµ¼µÄÒÖÖÆ×÷ÓÃÊÇͨ¹ý´Ù½øÁܰͽáÖп¹Ô­ÌØÒìÐÔTϸ°ûµÄµòÍö²¢Í¬Ê±½µµÍTregsµÄµòÍöÀ´ÊµÏֵġ£PD1Ðźű»Ö×ÁöÓÃÓÚÌÓ±ÜÃâÒßɱÉË£¬Òò´ËÓÃPD1ÐźÅ×è¶Ï¼ÁÀ´ÓÕµ¼¿¹Ö×ÁöÃâÒßÓ¦´ðµÄ·½·¨Òѱ»FDAÅú×¼ÓÃÓÚ°©Ö¢µÄÃâÒßÖÎÁÆ¡£

CD28HºÍB7-H7

CD28H(CD28 homolog) ±í´ï¹ã·º£¬µ«Ö÷Òª¼¯ÖÐÓÚÉÏƤºÍÄÚƤϸ°û¡£ËüÔÚÁÜ°Í×éÖ¯ºÍÍâÖÜѪµ¥¸öºËϸ°û(ÈçNKϸ°ûºÍCD3+Tϸ°û)ÖÐÒ²Óбí´ï¡£ÆäÅäÌåB7-H7±í´ïÓÚ¶àÖÖ×éÖ¯¡£ÔÚÃâÒßϸ°ûÖУ¬B7-H7ÔÚBϸ°û¡¢Ê÷ͻ״ϸ°ûºÍ¾ÞÊÉϸ°ûÖи߱í´ï£¬¶øÔÚTϸ°ûÖбí´ï²»¸ß¡£CD28HÓëB7-H7µÄÏ໥×÷Óù²´Ì¼¤ÒýÆðÈËTϸ°ûµÄÉú³¤ºÍϸ°ûÒò×ӵIJúÉú¡£

TIM3ºÍGAL9

TIM-3(T cell Immunoglobulin Domain and Mucin Domain 3)ÊôÓÚÃâÒßÇòµ°°×³¬¼Ò×壬Æä¸ß±í´ïÓÚTh1ÁÜ°Íϸ°ûºÍCD11b+¾ÞÊÉϸ°û£¬Tϸ°ûºÍËèϵϸ°û»î»¯Ê±±í´ïÉϵ÷¡£TIM-3µ÷½Ú¾ÞÊÉϸ°ûµÄ»î»¯£¬²¢Í¨¹ýÒÖÖÆTh1½éµ¼µÄÃâÒßÓ¦´ð¶ø´Ù½øÃâÒßÄÍÊÜ¡£GAL9 (Galectin-9)ÊÇTIM-3µÄÅäÌåÖ®Ò»£¬ÊôÓÚÄý¼¯ËØ(lectins)ÖеİëÈéÌÇÄý¼¯ËØ(galectins)¼Ò×å¡£GAL9ÓëTIM-3µÄ½áºÏ¿É¸ºÏòµ÷¿ØTh1ÐÍÃâÒßÓ¦´ð£¬ÔöÇ¿ÃâÒßÄÍÊÜ£¬²¢ÒÖÖÆ¿¹Ö×ÁöÃâÒß¡£TIM-3:GAL9ÐźÅ;¾¶µÄʧµ÷Óë¶àÖÖÂýÐÔ×ÔÉíÃâÒß

¼²²¡£¬Èç¶à·¢ÐÔÓ²»¯Ö¢ºÍϵͳÐÔºì°ßÀÇ´¯µÈÓйØ¡£

ICOSºÍICOSL

ICOS±í´ïÔڻµÄTϸ°ûÉÏ£¬¶øÆäÅäÌåICOSLÔÚ¿¹Ô­µÝ³Êϸ°û£¬ÈçBϸ°û¡¢¾ÞÊÉϸ°û¡¢µ¥ºËϸ°ûºÍÊ÷ͻ״ϸ°ûµÈ±íÃæ±í´ï¡£ICOSºÍÆäÅäÌåICOSLµÄÏ໥×÷Óý鵼Tϸ°û»î»¯ºÍÀ©Ôö£¬²¢²ÎÓëTϸ°ûÒÀÀµµÄBϸ°û»î»¯ºÍThϸ°ûµÄ·Ö»¯¡£

KIRºÍMHC-I

KIRs(Killer cell immunoglobulin-like receptors)ÊÇÊôÓÚÃâÒßÇòµ°°×³¬¼Ò×åµÄÒ»¸öÊÜÌå¼Ò×壬±í´ïÔÚNKϸ°ûºÍijЩTϸ°ûÑÇȺÉÏ¡£KIRsÓë±í´ïÔÚËùÓÐϸ°ûÉϵÄMHC-IÀà·Ö×ÓÏ໥×÷Ó㬵÷½ÚNKϸ°ûºÍTϸ°ûÑÇȺµÄɱÉ˹¦ÄÜ¡£¶àÊýKIRͨ¹ýÉÏÊöÏ໥×÷ÓÃÀ´ÒÖÖÆNK ϸ°ûµÄϸ°û¶¾»îÐÔ¡£

B7-H3ºÍδ֪ÊÜÌå

B7-H3(B7 homolog 3)ÊôÓÚÃâÒßÇòµ°°×³¬¼Ò×åµÄB7¼Ò×壬´ó¶à±í´ïÔÚרְµÄ¿¹Ô­µÝ³Êϸ°ûÉÏ¡£ËüÊǸºÐÔµ÷¿Ø·Ö×Ó£¬¾ßÓÐÒÖÖÆTϸ°û»î»¯ºÍϸ°ûÒò×Ó²úÉúµÄ»îÐÔ¡£B7-H3µÄÊÜÌåδ֪¡£

B7-H4ºÍδ֪ÊÜÌå

B7-H4(B7 homolog 4)ÊôÓÚÃâÒßÇòµ°°×³¬¼Ò×åµÄB7¼Ò×壬Æä±í´ïÔڻµÄÁÜ°Íϸ°û¡¢¾ÞÊÉϸ°û¡¢µ¥ºËϸ°û¡¢Ê÷ͻ״ϸ°û¡¢ÉÏƤϸ°û¡¢¹ÇËèÀ´Ô´µÄ¼ä³äÖʸÉϸ°ûºÍÖ×Áöϸ°ûÉÏ¡£ËüÊÇTϸ°ûÃâÒߵĸºÐÔµ÷¿Ø·Ö×Ó£¬¾ßÓÐÒÖÖÆTϸ°ûÔöÖ³¡¢Ï¸°ûÒò×Ó²úÉúºÍϸ°ûÖÜÆÚ½øÕ¹µÄ¹¦ÄÜ¡£B7-H3µÄÊÜÌåδ֪¡£

Ö×Áö»µËÀÒò×ÓÊÜÌ峬¼Ò×å (TNFRSF)

Ä¿Ç°ÒÑÖª£¬TNFRSFÔÚÈËÀàÖаüº¬29¸öÊÜÌåºÍ19¸öÅäÌ壬¾ùÊÇÖ×Áö»µËÀÒò×Ó(TNF)µÄͬԴÎËüÃÇͨ¹ýϸ°ûÍâÒ»¸ö¸»º¬°ëë×°±ËáµÄÇøÓòÓëÅäÌå½áºÏ¡£¶àÊýTNFÊÜÌåÐèÔÚϸ°û½¬Ä¤±íÃæÐγÉÈý¾ÛÌåºó·½¿É·¢»Ó»îÐÔ£¬¶øÇÒ¶àÐè½ÓÍ·µ°°×À´½éµ¼ÆäÏÂÓεÄÐźÅתµ¼¡£TNFÊÜÌåÖ÷Òª²ÎÓëϸ°ûµòÍöºÍÑ×Ö¢£¬Ò²ÔÚÆäËüÐźÅ;¾¶£¬ÈçÔöÖ³¡¢´æ»îºÍ·Ö»¯Öз¢»Ó×÷Ó᣸üÒ×åµÄijЩ³ÉÔ±º¬Óаû½¬¡°ËÀÍö½á¹¹Óò¡±£¬¸Ã½á¹¹Óò¶ÔµòÍöÓ¦´ðµÄÆô¶¯ÖÁ¹ØÖØÒª¡£

HVEMºÍLIGHT/BTLA/CD160

HVEM(Herpes Virus Entry Mediator)ÊÇTNFRSFµÄÒ»Ô±£¬ÏµÍ³ÃüÃûΪTNFRSF14¡£HVEM¹ã·º±í´ïÔÚAPCs¡¢ÄÚƤºÍÁÜ°Íϸ°û£¬ÓÈÆäÊdzõʼTϸ°ûÉÏ¡£HVEM×÷ΪÊÜÌåÓжà¸öÅäÌ壬°üÀ¨ÊôÓÚÃâÒßÇòµ°°×³¬¼Ò×åµÄLIGHT¡¢BTLA£¬ÒÔ¼°CD160¡£
LIGHTÔڻµÄTϸ°û¡¢NKϸ°û¡¢µ¥ºËϸ°û¡¢Á£Ï¸°ûºÍδ³ÉÊìµÄÊ÷ͻ״ϸ°ûÉϱí´ï£¬Æ书ÄÜÊǵ±ÓëHVEM½áºÏʱ·¢»Ó¹²´Ì¼¤×÷Ó㬴Ӷø»î»¯ÁÜ°Íϸ°û¡£ÓëLIGHTÏà·´£¬BTLAºÍCD160´«µÝÒÖÖÆÐźţ¬ËüÃÇÓëHVEM½áºÏʱ×èÖÍTϸ°ûµÄ»î»¯¡£BTLA

±í´ïÓÚÆ¢ÔàTϸ°ûºÍBϸ°û£¬¾ÞÊÉϸ°û¡¢NKϸ°ûºÍÊ÷ͻ״ϸ°û£¬¶øCD160ÓÉNKϸ°û£¬NKTϸ°û£¬¦Ã/¦ÄTϸ°û£¬Tϸ°û£¬ÒÔ¼°ËùÓг¦ÉÏƤÄÚÁÜ°Íϸ°û±í´ï¡£

4-1BBºÍ4-1BBL

4-1BB(TNFRSF9)Ö÷Òª±í´ïÔڻµÄCD4+ºÍCD8+T£¬»î»¯µÄBϸ°û£¬Ê÷ͻ״ϸ°ûºÍNKϸ°ûÉÏ£¬¶øÆäÅäÌå4-1BBL (TNFSF9)Ö÷Òª±í´ïÔÚ¿¹Ô­µÝ³Êϸ
°û£¬»î»¯µÄBϸ°ûºÍTϸ°ûÉÏ¡£Tϸ°ûºÍNKϸ°ûÉÏ

µÄ4-1BBÓëÆäÅäÌåµÄÏ໥×÷ÓÃÓÕµ¼Ï¸°ûµÄ»î»¯ºÍ´æ»î£¬²¢ÔöÇ¿ÕâЩϸ°ûµÄЧӦ¹¦ÄÜ¡£

OX40ºÍOX40L

OX40(TNFRSF4)ÔÚ¶àÖÖTϸ°û£¬NKϸ°û£¬NKTϸ°ûºÍÖÐÐÔÁ£Ï¸°ûÉϱí´ï¡£ÓëCD28²»Í¬£¬OX40²»×é³ÉÐͱí´ïÔÚ¾²Ï¢µÄ³õʼTϸ°ûÉÏ¡£OX40ÊÇÒ»ÖÖ³Ù·¢Ð͹²´Ì¼¤ÃâÒß¼ì²éµã·Ö×Ó£¬Ï¸°û»î»¯ºó24-72Сʱ±í´ï¡£ÆäÅäÌåOX40LÔÚ¿¹Ô­µÝ³Êϸ°û£¬

ÈçÊ÷ͻ״ϸ°û¡¢Bϸ°ûºÍ¾ÞÊÉϸ°ûÉϱí´ï£¬Ñ×֢ʱ±í´ï¸ü¹ã·º¡£OX40L½ö±í´ïÔڻµÄ¿¹Ô­µÝ³Êϸ°ûÉÏ£¬¶øÔÚ¾²Ï¢µÄ¿¹Ô­µÝ³Êϸ°ûÉϲ»±í´ï¡£OX40²ÎÓë»î»¯Tϸ°ûÑÇȺµÄ´æ»îºÍÀ©Ôö£¬ÒÔ¼°Tϸ°û¼ÇÒäµÄ½¨Á¢¡£

GITRºÍGITRL

GITR(glucocorticoid-induced TNFR-related protein, TNFRSF18)×é³ÉÐͱí´ïÔÚTregϸ°ûÉÏ£¬¶ø¶ÔÓÚ¾²Ï¢µÄCD4+ºÍCD8+Tϸ°û£¬GITRÔڻºó24Сʱ±í´ïÉϵ÷£¬ÇÒ»á³ÖÐø¸ß±í´ïÊýÌì¡£GITRÒ²±í´ïÔÚÆäËüϸ°û£¬ÈçÊ÷ͻ״ϸ°û£¬µ¥ºËϸ°ûºÍNKϸ

°ûÉÏ¡£ÆäÅäÌåGITRL¸ß±í´ïÔڻµÄ¿¹Ô­µÝ³Êϸ°ûºÍÑ×Ö¢²¿Î»µÄÄÚƤϸ°ûÉÏ¡£GITR·Ö±ðͨ¹ý´Ì¼¤ÔöÖ³ºÍ´Ù½øTϸ°ûµÄ´æ»î¶øά³ÖЧӦTϸ°ûµÄ»îÐÔºÍЧӦ¹¦ÄÜ¡£ÓÉGITRÒýÆðµÄTreg»îÐÔÊÜÒÖ¼ä½ÓÓ°Ïì×ÅTЧӦϸ°û¹¦Äܵķ¢»Ó¡£

CD27ºÍCD70

CD27(TNFRSF7)ÊÇÒ»ÖÖ¹²´Ì¼¤·Ö×Ó£¬×é³ÉÐͱí´ïÔÚЧӦÐÔTϸ°û¡¢¼ÇÒäÐÔBϸ°ûºÍNKϸ°ûµÄÒ»¸öÑÇȺÉÏ¡£ÆäÅäÌåCD70±í´ïÔڸ߶ȻµÄÁÜ°Íϸ°ûÉÏ£¬ÔÚijЩÖ×ÁöÉϵıí´ïˮƽ·Ç³£¸ß¡£CD27µÄ½»Áª²ÎÓëNKϸ°ûµÄ»î»¯ºÍ´æ»î£¬Tϸ°ûЧӦ¹¦ÄܵÄ
³ÖÐø·¢»Ó£¬Tϸ°û¼ÇÒäµÄÐγɣ¬Éú·¢ÖÐÐĵÄÐγɣ¬Bϸ°ûµÄ³ÉÊìÒÔ¼°¸ßÇ׺ÍÁ¦IgG¿¹ÌåµÄ²úÉú¡£

CD30ºÍCD153

CD30(TNFRSF8)ÓɻµÄTϸ°ûºÍBϸ°û±í´ï£¬ÔÚ¾²Ï¢Tϸ°ûºÍBϸ°ûÉϲ»±í´ï¡£CD30µÄÅäÌåCD153±í´ïÔڻµÄTϸ°ûÉÏ¡£CD30ºÍCD153µÄ½»Áª½éµ¼¶àÖÖÉúÎïѧЧӦ£¬°üÀ¨Ï¸°ûÔöÖ³¡¢»î»¯¡¢·Ö»¯ºÍµòÍö¡£CD30ÔÚ¶àÖÖ¶ñÐÔѪҺÖ×ÁöÖйý±í´ï£¬
ÔÚÂýÐÔÑ×Ö¢ºÍ×ÔÉíÃâÒß¼²²¡(Èçºì°ßÀÇ´¯£¬Ïø´­ºÍÀà·çʪÐԹؽÚÑ×)»¼Õߵİ×ϸ°ûÖÐÒ²Óз¢ÏÖ¡£

CD40ºÍCD154

CD40(TNFRSF5)±í´ïÔÚÄÚƤϸ°û£¬±íƤϸ°û£¬¿¹Ô­µÝ³Êϸ°û(°üÀ¨Bϸ°û£¬Ê÷ͻ״ϸ°ûºÍ¾ÞÊÉϸ°û)£¬ÒÔ¼°¶àÖÖÖ×Áöϸ°ûµÄ±íÃæ¡£ÆäÅäÌåCD154ÔڻµÄTϸ°û£¬ÑªÐ¡°åºÍijЩÆäËüϸ°ûÉϱí´ï¡£CD40µÄ»î»¯²ÎÓëÉú·¢ÖÐÐĵÄÐγɣ¬Bϸ°û·¢ÓýºÍÃâ

ÒßÇòµ°°×µÄÀà±ðת»»¡£CD40ÓëCD154µÄÏ໥×÷ÓöÔÓÚ¹²´Ì¼¤ºÍÃâÒßµ÷½Ú·Ç³£ÖØÒª¡£CD40Ò²²ÎÓë¶àÖÖÐÄѪ¹Ü¼²²¡£¬È綯ÂöÖàÑùÓ²»¯ºÍ¶¯ÂöÖàÑùÓ²»¯ÑªË¨µÄ²¡Àí·¢

LAG3ºÍMHC-II

LAG3 (Lymphocyte-activation gene 3)±í´ïÔڻµÄTϸ°û£¬NKϸ°û£¬Bϸ°ûºÍ½¬Ï¸°ûÑùDCÉÏ¡£ÆäÖ÷ÒªµÄÅäÌåÊÇ×é³ÉÐͱí´ïÔÚרְ¿¹Ô­µÝ³Êϸ°ûÉϵÄMHC-IIÀà·Ö×Ó¡£LAG3ÓëMHC-IIÀà·Ö×ӵĽáºÏÀàËÆÓÚÓëCD4µÄ½áºÏ£¬µ«Ç׺ÏÁ¦¸ü¸ß¡£LAG3ÒÔÓë

CTLA-4ºÍPD-1ÏàËƵķ½Ê½¸ºÐÔµ÷¿ØTϸ°ûµÄÔöÖ³£¬»î»¯ºÍTϸ°ûµÄÎÈ̬¡£



²Î¿¼ÎÄÏ×:

1. Ceeraz, S., Nowak, E. C., Burns, C. M., & Noelle, R. J. (2014). Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. Arthritis research & therapy, 16(5), 469.

2. Chen, L., & Flies, D. B. (2013). Molecular mechanisms of T cell co-stimulation and co-inhibition. Nature Reviews Immunology, 13(4), 227-242.
3. Croft, M. (2003). Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nature Reviews Immunology, 3(8), 609-620.
4. Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015). Combination cancer immunotherapy and new immunomodulatory targets. Nature reviews Drug discovery, 14(8), 561-584.
5. M¨¢rquez-Rodas, I., Cerezuela, P., Soria, A., Berrocal, A., Riso, A., Gonz¨¢lez-Cao, M., & Mart¨ªn-Algarra, S. (2015).Immune checkpoint inhibitors: therapeutic advances in melanoma. Annals of translational medicine, 3(18), 267-282.
6. Nguyen, L. T., & Ohashi, P. S. (2015). Clinical blockade of PD1 and LAG3 - potential mechanisms of action. Nature Reviews Immunology, 15(1), 45-56.
7. Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer,12(4), 252-264.
8. Sharpe, A. H. (2009). Mechanisms of costimulation. Immunological reviews, 229(1), 5-11.

9. Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015). Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer cell, 27(4), 450-461.



PeproTechÖØ×éµ°°×



PeproTech(BioGems)SAFIRE¿¹Ìå

SAFIRE(Sodium Azide Free Immensely Reduced Endotoxins)Àà²úÆ·ÊÇBioGemsÆ·ÅÆÏµĹ¦ÄÜÐÔ¿¹Ìå²úÆ·£¬¾­ÌØÊ⹤ÒÕÉú²ú¡¢´¿»¯£¬¾ßÓÐÖî¶àÓŵ㣬¿ÉÓÃÓÚÃâÒßϸ°û¹¦Äܵļ¤»î¡¢×è¶Ï¡¢ÖкÍÑо¿£¬ÊÇÖ×ÁöÃâÒßÑо¿µÄÖØÒª¹¤¾ß¡£







ÓÊÏä
email
info@zvxcbio.com
µç»°
PHONE
0512-6789 5080
QQ
QQ
3440695713
µØÖ·
Company address
½­ËÕÊ¡ËÕÖÝÊй¤ÒµÔ°Çøԣз168ºÅÂöɽÁú´óÏÃ2´±
ÍøÕ¾µ¼º½
²úÆ··ÖÀà
ɨһɨ¹Ø×¢ÎÒÃÇ
ɨһɨ¹Ø×¢ÎÒÃÇ
¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿